Cargando…

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study

Context: CLL and indolent NHL are hematologic malignancies that typically result in immune dysfunction. Infection represents a major cause of morbidity and mortality in these patients. Patients with CLL and NHL are at higher risk of hospitalization and death from COVID-19.3 Data is lacking regarding...

Descripción completa

Detalles Bibliográficos
Autores principales:	St-Pierre, Frédérique, Doukas, Peter, Boyer, Jennifer, Nieves, Mariana, Ma, Shuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Acute Lymphoblastic Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489270/ http://dx.doi.org/10.1016/S2152-2650(22)01335-0

Ejemplares similares

Poster: CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
por: Trajkova, Sanja, et al.
Publicado: (2022)

CLL-393 Outcomes of COVID-19 Infections in Patients With Hematological Malignancies in Republic of North Macedonia
por: Cvetanoski, Milche, et al.
Publicado: (2022)

CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022)

ALL-083 ALLogeneic Hematopoietic Stem Cell Transplantation of a R/R T-ALL Patient Given Nelarabine, 3 Weeks Post Moderate COVID-19 Infection in the Local Setting
por: Uong, Flaryll
Publicado: (2022)

ALL-206 Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country
por: Hammad, Mahmoud, et al.
Publicado: (2022)

AML-174 Dilemma of Treating Acute Myeloid Leukemia Patient After Kidney Transplant in the COVID-19 Era
por: El-Ashwah, Shaimaa, et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T-cell acute lymphoblastic leukemia cells
por: Kuzilková, Daniela, et al.
Publicado: (2021)

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
por: Kayser, Sabine, et al.
Publicado: (2022)

High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL
por: Cabannes-Hamy, Aurélie, et al.
Publicado: (2022)

Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials
por: Creasey, Thomas, et al.
Publicado: (2021)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
por: Thielemans, Naomi, et al.
Publicado: (2022)

Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes
por: Anastasopoulou, Stavroula, et al.
Publicado: (2022)

Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)
por: Tasian, Sarah K., et al.
Publicado: (2022)

In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia
por: Van Trimpont, Maaike, et al.
Publicado: (2022)

Genome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia
por: Lalonde, Marie-Eve, et al.
Publicado: (2022)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia
por: Lim, Fang Qi, et al.
Publicado: (2022)

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement
por: Bomken, Simon, et al.
Publicado: (2022)

STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of BCL and BCLXL following glucocorticoid treatment
por: van der Zwet, Jordy C.G., et al.
Publicado: (2022)

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Wayne, Alan S., et al.
Publicado: (2022)

Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade
por: Woess, Katharina, et al.
Publicado: (2022)

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
por: González-Gil, Celia, et al.
Publicado: (2022)

Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia
por: Masic, Dino, et al.
Publicado: (2022)

General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
por: Gökbuget, Nicola, et al.
Publicado: (2023)

B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow
por: Barz, Malwine J., et al.
Publicado: (2022)

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3’ neo-enhancer
por: Smith, Charlotte, et al.
Publicado: (2023)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

RNA helicase DHX15 exemplifies a unique dependency in acute leukemia
por: Guo, Hao, et al.
Publicado: (2023)

Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study
por: Orvain, Corentin, et al.
Publicado: (2023)

Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia
por: Heilmann, Janina, et al.
Publicado: (2023)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aaookghj2nlgc9o3l0nfhpie4k